Results
Bharat Parenterals FY26 Transition Year, Innoxel Inflection
Bharat Parenterals reported FY26 as a transition year with consolidated revenue of ₹345.4 crore, flat YoY, but EBITDA surged 485% to ₹15.8 crore.
Subsidiary Innoxel Lifesciences grew 174% to ₹72.4 cro
